Drug
Avance Nerve Graft
Avance Nerve Graft: highest development phase Post-Market, developed by Axogen Corporation. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Axogen Corporation
Trials
| Drug | Phase | Indication |
|---|---|---|
| Avance Nerve Graft NCT07657182 | Post-Market | Peripheral Nerve Injury |
Latest
No recent events.
Follow Avance Nerve Graft on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.